These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8032250)

  • 1. Structure-based design of symmetric inhibitors of HIV-1 protease.
    Erickson J; Kempf D
    Arch Virol Suppl; 1994; 9():19-29. PubMed ID: 8032250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
    Erickson J; Neidhart DJ; VanDrie J; Kempf DJ; Wang XC; Norbeck DW; Plattner JJ; Rittenhouse JW; Turon M; Wideburg N
    Science; 1990 Aug; 249(4968):527-33. PubMed ID: 2200122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis.
    Abdel-Meguid SS; Zhao B; Murthy KH; Winborne E; Choi JK; DesJarlais RL; Minnich MD; Culp JS; Debouck C; Tomaszek TA
    Biochemistry; 1993 Aug; 32(31):7972-80. PubMed ID: 8347601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.
    Kempf DJ; Marsh KC; Paul DA; Knigge MF; Norbeck DW; Kohlbrenner WE; Codacovi L; Vasavanonda S; Bryant P; Wang XC
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2209-14. PubMed ID: 1803993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms--structure/function relationship and influence of crystal packing.
    Lange-Savage G; Berchtold H; Liesum A; Budt KH; Peyman A; Knolle J; Sedlacek J; Fabry M; Hilgenfeld R
    Eur J Biochem; 1997 Sep; 248(2):313-22. PubMed ID: 9346283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease.
    Rao BG; Murcko MA
    Protein Eng; 1996 Sep; 9(9):767-71. PubMed ID: 8888142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.
    Mo H; Markowitz M; Majer P; Burt SK; Gulnik SV; Suvorov LI; Erickson JW; Ho DD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):55-61. PubMed ID: 8825619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.
    Ho DD; Toyoshima T; Mo H; Kempf DJ; Norbeck D; Chen CM; Wideburg NE; Burt SK; Erickson JW; Singh MK
    J Virol; 1994 Mar; 68(3):2016-20. PubMed ID: 8107264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
    Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
    Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors.
    King RW; Winslow DL; Garber S; Scarnati HT; Bachelor L; Stack S; Otto MJ
    Antiviral Res; 1995 Sep; 28(1):13-24. PubMed ID: 8585757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.
    Priestle JP; Fässler A; Rösel J; Tintelnot-Blomley M; Strop P; Grütter MG
    Structure; 1995 Apr; 3(4):381-9. PubMed ID: 7613867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols.
    Budt KH; Peyman A; Hansen J; Knolle J; Meichsner C; Paessens A; Ruppert D; Stowasser B
    Bioorg Med Chem; 1995 May; 3(5):559-71. PubMed ID: 7648204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.